**University of Leicester**

**MRC AIM Studentship Project 2025-6 entry.**

|  |  |
| --- | --- |
| **First Supervisor** | Prof Sylwia Bujkiewicz |
| **School/Department** | Department of Population Health Sciences |
| **Email** | [sylwia.bujkiewicz@le.ac.uk](mailto:sylwia.bujkiewicz@le.ac.uk) |

|  |  |
| --- | --- |
| **Second Supervisor** | Prof Richard Riley / Dr Sam Khan |
| **School/Department** | Department of Applied Health Sciences, School of Health Sciences, University of Birmingham  Department of Genetics, Genomics and Cancer Sciences |
| **Email** | [r.d.riley@bham.ac.uk](mailto:r.d.riley@bham.ac.uk) / [sk504@le.ac.uk](mailto:sk504@le.ac.uk) |

|  |  |
| --- | --- |
| **Additional Supervisor** |  |

**Section 2 – *Project Information***

|  |  |
| --- | --- |
| **Project Title** | Analytic methods for leveraging complex data to inform effective evaluation of cancer therapies |
| **Project Summary** | |
| This PhD project will focus on application and development of methods for evaluation of the effectiveness of cancer therapies. Modern cancer therapies are often developed for subsets of patients harbouring a particular biomarker. Therefore, clinical trials evaluating the effectiveness of cancer therapies may be small, resulting in uncertainty about the effectiveness of these therapies; for example, in improving patients’ survival. This project will investigate efficient methods for combining diverse data to improve the precision of the effectiveness estimates. In turn, it will help improve the efficiency of important decisions about which new therapies are available to patients.  You will apply a range of modern tools from biostatistics, including Bayesian analysis, and data science to evaluate cancer therapies. You will use diverse data from clinical trials, including alternative outcomes (other than survival) or different cancers, and data collected routinely in hospitals available from electronic health records.  You will benefit from an experienced supervisory team, including academics from the University of Leicester and the University of Birmingham and experts from industry from AstraZeneca, with expertise in statistics, data science and oncology. The project will provide an opportunity to develop a range of analytical skills and gain insight into drug development processes. | |
| **References** | |
| 1. **Singh J**, Anwer S, Palmer S, Saramago P, Thomas AL, Dias S, Soares M, **Bujkiewicz S**, Multi-indication evidence synthesis in oncology health technology assessment, Medical Decision Making (in press, preprint available at <https://arxiv.org/abs/2311.12452>). 2. Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V. Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without bevacizumab for people with advanced non‐small cell lung cancer. *Cochrane Database of Systematic Reviews*. 2020(12). 3. Narayan, V., Kahlmeyer, A., Dahm, P., Skoetz, N., Risk, M.C., Bongiorno, C., Patel, N., Hwang, E.C., Jung, J.H., Gartlehner, G. and Kunath, F., 2018. Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. *A Cochrane Rapid Review. Cochrane Database of Systematic Reviews*, (7). 4. Unverzagt S, Moldenhauer I, Nothacker M, Rossmeissl D, Hadjinicolaou AV, Peinemann F, Greco F, Seliger B. Immunotherapy for metastatic renal cell carcinoma. *Cochrane Database of Systematic Reviews*. 2017(5). 5. Goldkuhle M, Dimaki M, Gartlehner G, Monsef I, Dahm P, Glossmann JP, Engert A, von Tresckow B, Skoetz N. Nivolumab for adults with Hodgkin’s lymphoma (a rapid review using the software RobotReviewer). *Cochrane Database of Systematic Reviews*. 2018(7). 6. Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. *American journal of epidemiology*. 2016 Apr 15;183(8):758-64. 7. Papanikos T, Thompson JT, Abrams KR, Städler N,  Ciani O, Taylor RS, **Bujkiewicz S**, [A Bayesian hierarchical meta-analytic method for modelling surrogate relationships that vary across treatment classes.](https://onlinelibrary.wiley.com/doi/epdf/10.1002/sim.8465) *Statistics in Medicine* 2020;39:1103–1124. 8. Poad H, **Khan S**, Wheaton L, Thomas AL, Sweeting M, **Bujkiewicz S**, The validity of surrogate endpoints in subgroups of metastatic colorectal cancer patients defined by treatment class and KRAS Status, Cancers 2022. 9. Schmitz S, Adams R, Walsh C. Incorporating data from various trial designs into a mixed treatment comparison model. *Statistics in medicine*. 2013 Jul 30;32(17):2935-49. 10. Jenkins D, Hussein H, Martina R, Dequen-O’Byrne P, Abrams KR, **Bujkiewicz S**, [Methods for the inclusion of real world evidence in network meta-analysis](https://bmcmedresmethodol.biomedcentral.com/track/pdf/10.1186/s12874-021-01399-3.pdf), BMC Medical Research Methodology 21, 207 (2021) 11. **S Bujkiewicz, J Singh**, L Wheaton, D Jenkins, R Martina, K Hyrich, KR Abrams, [Bridging disconnected networks of first and second lines of biologic therapies in rheumatoid arthritis with registry data: Bayesian evidence synthesis with target trial emulation](https://www.sciencedirect.com/science/article/pii/S0895435622001627), Journal of Clinical Epidemiology 2022; 150: 171-178 12. [L Wheaton](https://arxiv.org/search/stat?searchtype=author&query=Wheaton%2C+L), [A Papanikos](https://arxiv.org/search/stat?searchtype=author&query=Papanikos%2C+A), [AL Thomas](https://arxiv.org/search/stat?searchtype=author&query=Thomas%2C+A)**,**[**S Bujkiewicz**](https://arxiv.org/search/stat?searchtype=author&query=Bujkiewicz%2C+S), Using Bayesian Evidence Synthesis Methods to Incorporate Real World Evidence in Surrogate Endpoint Evaluation (2022) Medical Decision Making. | |